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Prohibited Substances
1. Anabolic Agents e.g.; Testosterone, Nandrolone etc
2. Hormones e.g.; Erythropoetin, Insulin etc
3. Diuretics e.g.; Albumin, Spironolactone etc
4. Beta-2-Agonists e.g.; Clenbuterol, Salbutamol, etc
Anabolic, Androgenic Steroids (AAS)
• Anabolic effect
– Accelerate muscle growth (protein synthesizing)
• Androgenic effect
– Develop masculine characteristics
• Anabolic androgenic steroids (AASs) are of two types:
– Endogenous 
• Produced naturally in the body
e.g. Testosterone (male sex hormone) 
– Exogenous   
• Synthetic derivatives of testosterone
e.g. Nandrolone, Stanozolol 
Dangers of Anabolic Steroids
Challenges faced by sports federations
• Urinalysis susceptible to false doping results
– e.g. Inter-individual and inter-ethnic variations in the 
prevalence of deletion polymorphism in gene coding of 
UGT2B17 (a steroid metabolizing enzyme) affects amount 
of glucuronidated metabolites produced
• Urine provides a short term history of drug use 
– Disadvantage in detecting out of competition doping
• Hair analysis, a possible approach to complement 
urinalysis
• Potentially misused as training drug for performance enhancement
• Use prohibited in and out of competition – World Anti-Doping Agency (WADA)
• Generally, doping with exogenous and endogenous AAS is determined by:
– Detecting glucuronide conjugates of the parent AAS and/or their Phase I 
metabolites in urine
• Supraphysiological administration of Testosterone is suspected when:
– The urinary ratio of Testosterone glucuronide (TG) to Epitestosterone 
glucuronide (EG) exceeds 4 (TG/EG>4)
• Epitestosterone (E) is an inactive epimer of Testosterone (T) 
• UGT2B17 
– Major enzyme involved in glucuronidation of most AASs [1]
AAS
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Advantages of hair specimens over urine
– Provides long term history of drug use, hence can 
identify athletes who use AAS during training and 
stop their use before competition
– Capable of facile detection of parent drug 
– Easy to collect and store
– Tamper resistant and non-intrusive 
– Negligible risk of infection   
AIMS
• To develop new methods for the determination of nandrolone 
and stanozolol in human hair using LC-MS/MS 
• To extend these newly developed methods for the determination 
of testosterone (T) and its inactive epimer epitestosterone (E) in 
human hair
• Thus, to estimate the physiological ratio of T/E in hair
• To study effect of pigment and use of other drugs on 
incorporation of AAS in hair
• To measure environmental contamination into potable water 
supplies of steroids
Liquid chromatography tandem 
mass spectrometry
SAMPLE PREPARATION

APPLICATIONS
Concentration of nandrolone and stanozolol in human hair  (n=180, 
108 Male, 72 female, 62% athletes) ELISA: 16 +ve Stanozolol, 3 +ve
Nandrolone
Sex Age Stanozololpg/mg
Nandrolone
pg/mg
Control * M 53 47.4 -
Athlete 1 M 22 5.0 -
Athlete 2 M 19 11.2 -
Athlete 3 M 21 33.0 -
Athlete 4 F 18 - 14.0
Athlete 5 F 19 9.8 -
Athlete 6 F 22 10.0 -
Athlete 7 F 20 12.7 -
Athlete 8 F 20 26.9 -
Athlete 9 F 18 40.2 -
Athlete 10 F 20 56.1 -
Athlete 11 F 22 63.3 -
Athlete 12 F 20 86.3 -
*Male bodybuilder who admitted use of stanozolol for the past 30 years by intramuscular
and oral route
Environmental
water sample
(N=3)
Average concentration pg/mL
31st
December
2009
18th
April
2010
21th
July
2010
01st
September
2010
24th
October
2010
05th
Novembe
r
2010
River Danube 1.82 ±
0.19
0.71 ±
0.06
0.54 ±
0.03
ND ND ND
Budapest Tap 1.19 ±
0.03
0.31 
(BLQ)
ND ND ND ND
Lake Balaton - ND - - - -
Spring ‘Rózsika’ - ND - - - -
Determination of stanozolol in
environmental and domestic water samples
Reasons for Reduction
• Variations in rates of contamination. In July 
2010 a new STP was commissioned.
• Dilution of river water due to rise in water 
levels.
• Degradation of the steroid in the river water 
due to other constituents in the river or 
photolysis etc. or deposition in the sediment.
• 3’Hydroxystanozolol, the metabolite was not 
detected.
Subject Male (n=49)
Age range 18 to 42 years
Analyte Testosterone (T) Epitestosterone (E) T/E ratio
Range 0.70 to 11.81 pg/mg 0.63 to 8.27 pg/mg 0.50 to 3.37
Average 2.67 pg/mg 2.46 pg/mg 1.33
Median 1.98 pg/mg 1.86 pg/mg 1.11
Standard error 0.29 0.34 0.13
Concentration of testosterone and epitestosterone 
in human hair 
Subject Female (n=26)
Age range 18 to 55 years
Analyte Testosterone Epitestosterone(detected in only 
7)
T/E ratio
Range 0.32 to 4.63 pg/mg 0.52 to 3.88 pg/mg 0.56 to 1.81 
Average 1.62 pg/mg 1.73 pg/mg 1.2
Median 1.03 pg/mg 1.23 pg/mg 1.30
Standard error 0.27 0.45 0.17
Animal Concentration of testosterone (pg/mg) Ratio of pigmented to non-pigmented
Pigmented 
hair
Non-pigmented 
hair
1 6.33 4.8 1.32
2 8.74 1.81 4.83
3 6.14 1.51 4.07
4 7.84 1.84 4.26
5 5.88 1.58 3.72
6 4.84 1.28 3.78
7 5.61 1.49 3.77
8 3.66 1.11 3.30
9 3.06 1.41 2.17
10 4.81 1.14 4.22
11 2.86 0.84 3.40
Mean ± SD 5.43 ± 1.85 1.71 ± 1.07 3.53 ± 1.00
Concentration of natural testosterone in 
pigmented and non-pigmented hair of rats
Influence of NSAIDs on Stanozolol 
excretion
Group Individual animals Diclofenac
G1 No. 1-6 0 mg/kg
G2 No. 7-12 1 mg/kg
G3 No. 13-18 5 mg/kg
G4 No. 19-24 25 mg/kg
Drug treatment and sample collection 
period
Concentrations of stanozolol and 3'-hydroxystanozolol in hair samples from groups G1, G2 and G3 
during stanozolol treatment (week 1, week 2 and week 3) and poststanozolol treatment period 
(week 4 and week 6)
CONCLUSIONS
• Methods developed are sensitive, specific, reliable and reproducible.
• LC-MS analysis does not require derivatisation unlike GC-MS.
• 20-50 mg hair required to detect 3 pg/mg nandrolone, 0.5 pg/mg 
stanozolol, 0.1 pg/mg testosterone and 0.25 pg/mg epitestosterone.
• Hair testing facilitates improved doping testing regimes that are non 
invasive, tamper resistant and benefit from facile storage and negligible 
risk of infection.
• Hair specimens can be used to compliment urinalysis.
• Concomitant use of other drugs (NSAIDs) and hair pigmentation affect 
levels of steroids. 
Mephedrone
• Former “legal high” which shows psychoactivity in humans
• Sometimes referred to as ‘meow’, ‘mcat’ and ‘bubbles’
• It is a β-ketoamphetamine and has a structure similar to     
methcathinone
• Routinely sold on the internet as plant feed
• In April 2010, it became a controlled drug under the Misuse of 
Drugs Act 1971 as a Class B substance (UK) 
O
NH
Aim:
The aim of the study was to develop a validated sensitive and 
reproducible method for the quantification of mephedrone and its 
two metabolites 4 – methylephedrine and 4 – normethylephedrine in 
human hair using liquid chromatography – mass spectroscopy.
mephedrone 4 – methylephedrine 4 – methylnorephedrine
O
NH
OH
NH
OH
NH2
Incorporation of drugs in hair
1. Endogenous 
pathway:
Passive diffusion 
of drugs from 
systemic 
circulation into 
hair via follicles
Endogenous–
exogenous 
pathway:
Absorption or 
transfer of drug 
molecules into 
hair shaft from 
transdermal 
excretion, sweat 
and sebum
Exogenous 
pathway:
Drugs deposited 
from external 
environment 
enter hair by 
absorption 
Three pathways
• Drug incorporation usually happens during the synthesis of melanin, 
where it gets bound to the melanin polymer.
Why use hair?
• It provides information on the long term history of the 
individual’s intake of drugs 
• Any kind of hair treatment such as bleaching cannot affect 
the incorporation of the drug into hair
• It is a non-invasive technique
• Easy storage, minimal degradation, Biosafe
• It can be used to compliment urinalysis for identifying 
routine drug users 
Compound (RT) 
min
Precursor 
ions (m/z)
Product 
ions(m/z)
Collision 
energy (eV)
Mephedrone 2.07 178.1 160.1
145.1
10
18
4-methylephedrine 1.93 180.2 147.2
131.3
115.2
19
18
39
4-methylnorephedrine 1.85 166.2 131.2
115.2
90.79
14
33
24
Mephedrone –d3 1.98 181.2 163.2
148.2
17
20
Ion transitions, retention time (RT) and collision energies used for the analysis of the analytes and the internal standard.
• Capillary temp: 3000C
• Voltage: 4000V 
• Collision pressure: 1.5mTorr 
Sample preparation:
Hair (50 mg) decontaminated (DCM) and 
pulverised
Enzymatic hair digestion with Proteinase K 
and Cleland’s Reagent 
Liquid-liquid extraction
Method Validation
Compound Concentration 
(pg/mg)
Precision RSD (%) Accuracy 
%Intraday    Interday
N=6+6+6 +6         N=18+18+18+18
Mephedrone 5
10
20
40
0.62
0.4
2.11
2.56
0.8
0.7
1.7
4.5
99.15
106.34
103.16
107.53
4 – methylephedrine 10
20
50
100
0.6
0.75
0.8
4.92
0.9
0.7
4
3.4
114.59
110.76
107.02
98.52
4–methylnorephedrine 10
20
50
100
0.54
0.2
2.91
6.97
1.1
0.7
2
7.3
107.98
106.51
97.6
100.67
Compound Recovery (%) at 
Conc. (20 pg/mg)
LOD
(pg/mg)
LOQ
(pg/mg)
Mephedrone 110.37 2.5 5
4-methylephedrine 98.37 5 10
4-methylnorephedrine 96.78 5 10
LC–MS/MS chromatogram and CID spectra of (a) mephedrone, (b) 4-methylephedrine and  (c) 4-
methylnorephedrine in hair at concentrations of 10pg/mg, 20pg/mg and 20pg/mg respectively.
(a)
(b)
(c)
• Out of 154 samples, mephedrone could be detected in four samples and
quantified in only one hair sample at a concentration of 21.11 pg/mg.
LC–MS/MS chromatogram and CID spectra of the positive sample 
Proposed metabolism pathway for mephedrone
• Due to the structural similarities of mephedrone to methcathinones
and methamphetamines, the metabolism of mephedrone has been 
proposed to follow a similar pathway. 
• There is a possibility of other pathways 
• The metabolites were not detected in any of the samples analysed.
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